| 2024 |
Oxidative Stress as a Target for Non-Pharmacological Intervention in MAFLD: Could There Be a Role for EVOO? |
Articolo in rivista |
Go to |
| 2023 |
FARMACI ANTIMICROTUBULARI |
Capitolo o Saggio |
Go to |
| 2023 |
MECCANISMI DI RESISTENZA AI FARMACI ANTITUMORALI |
Capitolo o Saggio |
Go to |
| 2023 |
FARMACI INIBITORI DELLE TOPOISOMERASI |
Capitolo o Saggio |
Go to |
| 2020 |
Meccanismi di resistenza ai farmaci antitumorali. |
Capitolo o Saggio |
Go to |
| 2020 |
Farmaci antimicrotubulari |
Capitolo o Saggio |
Go to |
| 2020 |
FARMACI INIBITORI DELLE TOPOISOMERASI |
Capitolo o Saggio |
Go to |
| 2019 |
Hepatotoxicity caused by mebendazole in a patient with Gilbert's syndrome |
Articolo in rivista |
Go to |
| 2019 |
STAT5 and STAT5 Inhibitors in Hematological Malignancies |
Articolo in rivista |
Go to |
| 2017 |
Effects of Pimozide Derivatives on pSTAT5 in K562 Cells |
Articolo in rivista |
Go to |
| 2017 |
Farmaci inibitori delle topoisomerasi |
Capitolo o Saggio |
Go to |
| 2017 |
Farmaci antimicrotubulari |
Capitolo o Saggio |
Go to |
| 2017 |
Meccanismi di resistenza ai farmaci antitumorali |
Capitolo o Saggio |
Go to |
| 2016 |
Novel iodoacetamido benzoheterocyclic derivatives with potent antileukemic activity are inhibitors of STAT5 phosphorylation |
Articolo in rivista |
Go to |
| 2015 |
The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients |
Articolo in rivista |
Go to |
| 2014 |
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: Synthesis and biological evaluation of valproic esters of 3’-C-methyladenosine |
Articolo in rivista |
Go to |
| 2014 |
4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors |
Articolo in rivista |
Go to |
| 2014 |
Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells
with new pimozide derivatives |
Articolo in rivista |
Go to |
| 2013 |
The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells. |
Articolo in rivista |
Go to |
| 2013 |
Farmacovigilanza attiva sul ruolo dei farmaci antiangiogenetici nell’osteonecrosi dei mascellari |
Proceedings |
Go to |
| 2013 |
The use of low molecular weight heparin in a Sicilian teaching hospital |
Proceedings |
Go to |
| 2012 |
Uso degli inibitori di pompa protonica in un Policlinico Universitario |
Articolo in rivista |
Go to |
| 2012 |
Epigenetic agents as an adjunct to active chemotherapy in hematological tumor cell lines |
Proceedings |
Go to |
| 2011 |
Histone deacetylase inhibition modulates deoxyribonucleotide pools and enhances the antitumor effects of the ribonucleotide reductase inhibitor 3’-C-methyladenosine in leukaemia cells |
Articolo in rivista |
Go to |
| 2011 |
Antitumor effects of novel co-drugs linking histone deacetylase and ribonucleotide reductase inhibitors in hematological tumors |
Proceedings |
Go to |
| 2009 |
Histone deacetylase (HDAC) inhibition modulates intracellular deoxynucleotides (dNTP) pools and potentiates the antitumor effects of the ribonucleotide reductase (RR) inhibitor 3’-Methyl-adenosine (3’-Me-Ado) in promyelocitic leukaemia cell lines. |
Proceedings |
Go to |
| 2008 |
Multidrug resistance reverting activity and antitumor profile of new phenothiazine derivatives |
Articolo in rivista |
Go to |
| 2008 |
Hydroxamic acid-containing histone deacetylase inhibitors potentiate the antiproliferative and apoptotic effects induced by the ribonucleotide reductase R1 inhibitor 3'-C-methyl-adenosine in promyelocytic leukemia cell lines |
Proceedings |
Go to |
| 2008 |
Histone deacetylase (HDAC) inhibitors potentiate the antiproliferative and apoptotic effects induced by the novel ribonucleotide reductase (RR) inhibitor 3'-metil-adenosine (3'-Me-Ado) in promyelocitic leukemia cell lines |
Proceedings |
Go to |
| 2008 |
Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells |
Articolo in rivista |
Go to |
| 2007 |
The synergistic apoptotic effects of thiophenfurin, an inosine monophosphate dehydrogenase inhibitor, in combination with retinoids in HL60 cells. |
Articolo in rivista |
Go to |
| 2007 |
Antitumor profile of new phenothiazine derivatives. |
Proceedings |
Go to |
| 2005 |
Farmaci antimicrotubulari. |
Monografia |
Go to |
| 2005 |
Cytotoxic and apoptotic effects of thiophenfurin in combination with retinoids in human promyelocitic leucemia HL60 cells |
Proceedings |
Go to |
| 2005 |
Induction of apoptosis by the adenosine derivative IB-MECA in parental or multidrug-resistant HL-60 leukemia cells: possibile relationship to the effects on inhibitor of apoptosis protein levels |
Articolo in rivista |
Go to |
| 2005 |
New trends in overcoming drug resistance in hepatocellular carcinoma. Looking for pharmacological inhibition of Inhibitory of Apoptosis Proteins (IAPs) by curcumin. |
Capitolo o Saggio |
Go to |
| 2005 |
Pterostilbene and 3'-hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells |
Articolo in rivista |
Go to |
| 2005 |
“Effects of combretastatin analogues on leukemic cell lines and normal hemopoietic cells” |
Proceedings |
Go to |
| 2005 |
Heterocyclic and Phenyl Double-Bond-Locked Combretastatin Analogues Possessing Potent Apoptosis-inducing activity in HL60 and in MDR Cell lines |
Articolo in rivista |
Go to |
| 2004 |
Expression of IAPs (Inhibitory of Apoptosis Proteins) and of their alternative splice variants in hepatocellular carcinoma tissues and cells |
Articolo in rivista |
Go to |
| 2004 |
Resistance to gemcitabine in a lymphoma cell line resistant to Fas-mediated apoptosis |
Articolo in rivista |
Go to |
| 2004 |
Expression of the IAPs in multidrug resistant tumor cells |
Articolo in rivista |
Go to |
| 2003 |
NF-kB inhibition restores sensitivity to Fas-mediated apoptosis in lymphoma cell lines |
Articolo in rivista |
Go to |
